Skip to main content

Sarepta Therapeutics Inc (NASDAQ:SRPT) Investor Investigation Concerning Potential Securities Laws Violations Announced

  • If you purchased shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to, or call us at (858) 779-1554.

Site Members can sign up for company wide alerts

Investigation Overview

April 26, 2016 (Update) - On April 25, 2016, Sarepta Therapeutics Inc issued a statemen on the advisory committee outcome for the use of its durg Eteplirsen in the treatment of Duchenne muscular dystrophy. Among other things, Sarepta Therapeutics Inc said that the advisory committee voted 6-7 against the finding of substantial evidence from adequate and well controlled studies that ...

You must register (for free) or login to view the entire investigation.